Not exactly. My focus was on thinking the some portion of the BK trials could be used toward FDA approval. As I stated in my conversations w TC, the US FDA approval is required before BK approaches anyone overseas for their approval. So if we need US trials, we are again relying on a large amount of NGIO funding thru common or preferred shares, and no further revenue will come from these deals until US trials are completed for FDA approval.